However, in a recently published pooled analysis of 2,310 BC patients with HER2 low-moderate expression, the authors showed that 3-year overall survival of HER2-low positive BC was significantly better than HER2-0 BC (91·6% vs 85·8%, p = 0.0016) [15]. This evidence concerns the gene ERBB2 and breast cancer.